Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Mental Health Startup, Taliaz, Inks Partnership Agreement with Molecular Diagnostics Leader, Genetic Technologies


Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX

“We are excited to partner with Genetic Technologies, world-leaders in the genetic risk assessment space. This new partnership will support rapid commercialization of PREDICTIX to help more depression sufferers in Australia, New Zealand and the USA.” Dekel Taliaz, CEO & Co-founder, Taliaz

Taliaz, a mental health startup harnessing artificial intelligence (AI) to revolutionize mental health treatment and management, today announced that it has entered into a three-year partnership agreement with molecular diagnostics leader, Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the ‘Company’) (GTG) for the distribution of its PREDICTIX products in Australia, New Zealand and the USA, pending regulatory approval.

Starting in the field of depression, the new agreement will accelerate global commercialization of Taliaz’s pioneering decision-support and management platform, while supporting GTG to expand its product offering and the establishment of a mental health vertical. This announcement follows Taliaz’s recent $2.7 Million EU Horizon funding awarded earlier this month.

Under the terms of the binding agreement, Taliaz will grant GTG exclusive distribution to its PREDICTIX products within Australia and New Zealand for a period of three years and non-exclusive distribution rights within the United States.

With 1 in 10 Americans [1] and 1 in 8 Australians [2] prescribed antidepressants per year, PREDICTIX empowers psychiatrists and general practitioners to provide a more accurate and rapid treatment plan for patients. This helps reduce treatment costs and the growing burden on society from depression.

The PREDICTIX technology uses AI to analyse multiple streams of patients’ data, including genetic, metabolic, demographic and clinical information. Doctors receive a personalized patient report that ranks the statistical efficacy and potential side effects of various antidepressant medications based on each patient’s genetic makeup and health record. PREDICTIX can improve today’s antidepressant prescribing accuracy by 47% [3].

PREDICTIX is CE-registered and commercially available in the UK, France and Israel, with the process underway for Therapeutic Goods Administration (TGA) approval in Australia.

Dekel Taliaz, CEO and Co-founder of Taliaz said, “We are excited to partner with Genetic Technologies, world-leaders in the genetic risk assessment space. This new partnership will support rapid commercialization of PREDICTIX to help more depression sufferers in Australia, New Zealand and the USA, while adding a complementary and advanced mental health solution to GTG’s growing suite of DNA tests.”

George Muchnicki, GTG’s Interim CEO stated: ‘We are incredibly pleased to have partnered with Taliaz to bring their predictive and personalized mental health product to Australia and New Zealand. GTG are at the forefront of providing personalized and predictive products to empower patients to make informed decisions about their health. This distribution agreement is our first external product partnership and our first product within the mental health vertical. Mental health has remained at the forefront of media discussions and government initiatives within Australia, New Zealand and globally due to the ongoing social and economic impact and given the impact from the current global pandemic. We look forward to working closely with the Taliaz team to deliver their product into these markets at this critical time.”

Taliaz is currently in the process of raising an additional round of investment to further accelerate and expand commercial efforts with healthcare systems, payors, providers, DNA laboratories and telemedicine providers globally.

Marketing Manager

Viki Gronau

Taliaz

M: +972-54-258-7278

E: viki@taliazhealth.com

Investor Relations (AUS)            

Stephanie Ottens                    

Market Eye                        

M: +61 434 405 400                    

E: stephanie.ottens@marketeye.com.au        

About Genetic Technologies

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit http://www.gtglabs.com

About Taliaz

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE-registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence, PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. Starting in the field of depression, the PREDICTIX Genetics and PREDICTIX Digital products can improve today’s prescribing accuracy by up to 47%4.

For more information, please visit predictix.ai.

1. Source: https://www.health.harvard.edu/blog/astounding-increase-in-antidepressant-use-by-americans-201110203624

2. Source: https://www.psychwatchaustralia.com/post/1-in-8-over-3-million-australians-are-on-antidepressants-why-is-the-lucky-country-so-miserable#:~:text=In%20the%202018%20financial%20year,SSRIs%20for%20depression%20or%20anxiety.&text=As%20shown%20in%20Table%201,antidepressant%2C%20in%202017%2D18.

3. Based on a retrospective analysis of STAR*D study medications versus current clinician treatment selection prescribing accuracy (Chekroud et al., 2016). STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration.

Share article on social media or email:

Revolutionizing Risk-Based Monitoring Through On-Study Analytics, Upcoming Webinar Hosted by Xtalks


With clinical trial resources prioritized by risk, RBM has brought study sponsors, CROs and other stakeholders greater oversight into how trials are conducted.

Since being officially condoned by the FDA in 2013, risk-based monitoring (RBM) has progressed to become a viable clinical monitoring technique, leveraging the latest technology to proactively identify challenges to trial safety, data analysis and compliance. With clinical trial resources prioritized by risk, RBM has brought study sponsors, CROs and other stakeholders greater oversight into how trials are conducted.

Could there be a better pathway for RBM – a more strategic approach that can optimize monitoring in real time?

In their upcoming webinar, Biorasi will be discussing a more sophisticated methodology for addressing RBM throughout the clinical trial. By introducing real-time analytics, RBM can empower trial stakeholders to make better decisions related to speed, cost and quality.

As part of this discussion on innovating RBM, Biorasi will be joined by data, analytics and technology partner IBM Watson Health, who will explore the importance of successful electronic data capture (EDC) to inform data management and analysis at all stages of the clinical trial. Biorasi encourages everyone to engage with the future of RBM by joining this webinar.

Join Roberto Silberwasser, VP, Data Sciences & Biometrics, and Geetesh Shrivastava, Director, Clinical Monitoring from Biorasi; along with Rob DiCicco, Deputy Chief Health Officer, and Sebastien Bohn, Offering Manager Lead – IBM Clinical Development, from IBM Watson Health, in the live webinar on Thursday, December 17, 2020 at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit Revolutionizing Risk-Based Monitoring Through On-Study Analytics.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Rare Cannabinoid Company adds extra high strength 3000mg CBD Booster to its line-up of THCV, CBN, CBG & CBC tinctures


3000mg CBD Booster, 500mg THCV, CBN, CBG, CBC tinctures

3000mg CBD Booster with 500mg THCV, CBN, CBG, CBC bottles by Rare Cannabinoid Company.

“Cannabinoids work best when taken together. We want our customers to have a lot of options so they can fully customize their wellness routines.”

Rare Cannabinoid Company has launched its latest uniquely high-dose hemp product: an extra high strength 3000mg CBD Booster.

The pioneering company leads the “rare” or “minor” cannabinoid industry as the first to offer tinctures of THCV for sale as well as single extracts of CBN oil, CBG, CBC, a full spectrum Rare Hawaiian CBD and one-to-one blends.

Each cannabinoid offers unique mental and physical benefits. With this in mind, Rare Cannabinoid Company’s Apothecary line was designed so that people could mix and match cannabinoids to customize their perfect blend for energy, sleep, appetite control or health and wellness needs. Now, those who wish to scale up their dose of CBD can do so easily.

The extra strength CBD Booster contains 3000mg CBD in organic MCT coconut oil. It comes with a measured glass dropper for precision dosing. This is because even a small amount of the oil contains a large amount of CBD. Each drop has 2.5mg CBD and each dropper-full has 25mg.

At just $99, it is priced extremely competitively. Better yet, the brand offers free shipping on all orders to anywhere in the United States and 15% off subscriptions.

Rare Cannabinoid Company also just launched a 1000mg full spectrum CBD extracted from rich Hawaiian hemp. It sells for $79. Meanwhile, their 500mg full spectrum Rare Hawaiian CBD and their 500mg CBG sell for $49 each.

“We want our products to be accessible to everyone who can benefit from them,” said Rare Cannabinoid Company founder and CEO Jared Dalgamouni.

“Cannabinoids work best when taken together. We want our customers to have a lot of options so they can fully customize their wellness routines.”

While CBD has taken the world by storm over the last few years, many people are just learning about the hemp and cannabis plants’ other cannabinoids now.

“Our biggest seller is THCV, followed by CBN,” said Dalgamouni.

THCV (tetrahydrocannabivarin) has an almost mythical standing in the cannabis world for its alleged uplifting, stimulating, appetite suppressing properties.

Leafly, the world’s largest cannabis information website, just published an article headlined: “Can THCV really curb the munchies?” According to the many scientific studies presented in the article, the answer appears to be a resounding “yes.” It functions in a similar fashion to a pharmaceutical anti-obesity drug without the drug’s negative side effects. By curbing the munchies, THCV may help people lose weight and be beneficial for those with type 2 diabetes. The article features Rare Cannabinoid Company as the gold-standard for where to buy THCV. Leafly also features the brand’s products in their article: “Looking for THCV, CBN, CBG, or CBC? Rare Cannabinoid Company has you covered“

While THCV is an ideal, energizing daytime cannabinoid, CBN (cannabinol) is believed to help people relax and fall asleep faster and stay asleep longer. In this blog on CBN for sleep, it was cited by Steep Hill laborites as being akin to pharmaceutical sleep aid Diazepam. It is also believed helpful for pain, inflammation and other ailments.

CBG (cannabigerol) is real health and wellness cannabinoid, with scientific studies saying it appears to work well for inflammation, fight bacteria, act as a neuroprotectant (aiding those with Parkinson’s, Alzheimer’s and other dementias as well as MS), and is being researched in the fight against cancer. You can find links to studies in this blog: What is CBG and what benefits does CBG offer?

CBC (cannabichromene) is known as a mood regulator and may also promote healthy skin by controlling acne. It is also known as an anti-inflammatory and is being researched for cancer use.

Rare Cannabinoid Company offers two lines: Apothecary and Ready Blends.

Apothecary products contain 500mg rare cannabinoid and are intended for mixing and matching or combining one’s own full or broad spectrum oil or the brand’s Rare Hawaiian CBD. Taking a spectrum of cannabinoids increases their effectiveness and offers the entourage effect.

Ready blends are whole hemp supplements that offer the entourage effect as they contain 250mg rare cannabinoid and 250mg full spectrum CBD.

The new extra high strength 3000mg CBD booster can be used to amplify the amount of CBD in any of these products.

For example, one could boost their morning THCV dose with it, add it to a CBG blend for relief after exercising or use it to enhance their CBN before bed.

All Rare Cannabinoid Company products contain large, quantifiable amounts of cannabinoids. This can be verified by looking at the independent lab test results posted on their website.

It is very important to check lab reports before purchasing hemp or cannabis products. Many sites that say “Buy THCV” or “CBN for sale” are actually selling full spectrum CBD products that are naturally slightly higher in THCV or CBN but nowhere near the amounts listed above. A popular tablingual brand sells THCV tablets that only contain 1mg THCV each. Even popular high-THCV cannabis flowers such as Doug’s Varin, Durban Poison, Tangie and Jack the Ripper often only contain 1 or 2% THCV. Dangerously, one brand that claimed to be selling THCV posted a lab report showing that it was actually THC! (THC is psychoactive and causes the munchies rather than taking them away).

Rare Cannabinoid Company strives to be completely transparent as it forges ahead into a new world of cannabinoid wellness. The company takes pride in listing its ingredients and lab reports clearly as well as offering links to all of the latest research into the potential health and wellness benefits of each cannabinoid.

“This is a very exciting time. We hope to see more and more cannabinoids being extracted, researched and offering people great benefits.” said founder Dalgamouni.

For more information, you can see the brand’s blog: “What are Rare Cannabinoids?” and learn about the world’s first pure tincture of THCV for sale online here.

Stores interested in stocking Rare Cannabinoid Company products can register for a wholesale account here.

Rare Cannabinoid Company is the sister brand of Hawaiian Choice, Hawaii’s most popular CBD brand. All Hawaiian Choice products contain broad spectrum Hawaiian CBD and are infused with organic or wild gathered tropical fruits, essential oils or honey. The luxury CBD products can be found in more than 150 locations from New York to Japan.

World Teacher and Happy Science Founder Ryuho Okawa publishes His Timely Work, “How to Survive the Coronavirus Recession”


How to Survive the Coronavirus Recession

How to Survive the Coronavirus Recession

An inspiring voice of hope for navigating these difficult times.

World Teacher and Happy Science CEO Ryuho Okawa has been an important and outspoken critic of the manner in which the novel coronavirus has been handled by governments throughout 2020. His newest publication on the topic, “How to Survive the Coronavirus Recession,” is a straightforward approach to the difficulties that many people are facing today. Unlike other works that discuss the novel coronavirus, which tend to focus upon how life has changed, or which simply question whether it is a hoax, Ryuho Okawa provides a constructive overview for surviving and thriving during these times.

The work begins with an overview of the present situation. According to Okawa, there is an unreasonably high amount of fear surrounding the novel coronavirus. Much of this fear has been promulgated by the media, and by politicians who take every word spoken by epidemiologists as though it is sacred; such is despite the fact that influenza has statistically been responsible for more deaths than the novel coronavirus. It is recommended that people maintain a healthy sense of skepticism in the midst of these times, especially where considerations of work are concerned.

To work is to nourish the human need for activity, progress, and purpose. At present, many people throughout the world are being instructed to refrain from working, and to refrain from helping one another. Okawa emphasizes that people should not be afraid to work, and that the government is not going to save everyone with a magic solution. Unemployment rates in the United States reached an all time high in 2020 due to mandates for people to remain home, and such has had terrible consequences for many people; this will continue unless leaders, and the general populace of humanity, assume a more courageous and constructive attitude.

Many people are afraid of the novel coronavirus and Okawa reminds the reader that by faithfully adhering to certain divine principles, those fears may be relinquished. It is important, for example, to accept the lifespan that God provides to each of us. It is explained that viral infections are akin to spiritual possession; what the mind believes is what the mind will attract. It is accordingly that fear will attract what is feared, while a positive attitude will attract what is positive. The belief in any superstition can make it real, but to deny a superstition is to nullify it.

Within this work the dynamics of viral infections, allergies, and overall health are examined in a context that balances deep spiritual insight with conventional wisdom. Faith in God is the most powerful immunity available to us, but other dynamics, such as consuming antioxidants which support the immune system, exercising, maintaining a balanced diet, and practicing meditation are also important. Okawa thoroughly explains the dynamics of each in such a manner that the reader is provided with a comprehensive formula for developing and maintaining a healthy mind and body which is capable of conquering the challenges of this time.

Like many of Ryuho Okawa’s works, “How to Survive the Coronavirus Recession” is a work written in order to provide hope and constructive guidance to the world during tumultuous times. Readers who are unsure of what direction to take at the present time will benefit from reading this book, as will any who have been negatively impacted by the novel coronavirus. Pick up your copy today and discover how, despite apparent limitations in the world today, it is nonetheless possible to strive forward in your own divine mission.

“How to Survive the Coronavirus Recession” is available at all major bookstores nationwide and online retailers, including Barnes & Noble and Amazon.

For in-depth commentary on the works of Ryuho Okawa, please listen to the Okawa Book Club podcast now streaming on Spotify, Apple Podcasts, and Amazon Music.

IRH Press USA

Share article on social media or email:

Visikol Launches Multiplex Slide Imaging and Analysis Services


The goal of immuno-oncology is threefold: to understand how key cells in the immune system interact with the tumor microenvironment, to understand how these interactions contribute to the outcome of the patient, and to modulate the immune response in a way that reduces tumor growth, ideally toward the elimination of tumor cells. The field of immuno-oncology has necessitated a rapid development of multiplex imaging technologies which allow for all of these markers to be identified from a single slide.

Over the last few years, several technological approaches have been developed to provide researchers with the ability to survey the immune system landscape on slides and to address these complex research questions. However, many of these technologies require expensive imaging or tissue processing equipment and the use of proprietary labeling techniques. The need to spend significant resources to adopt these technologies has limited their widespread use and the inability to use traditionally validated antibodies increases the overall barrier to adoption.

It is because of these short-comings and the need for an easy-to-use multiplexing tool that Visikol has developed a novel multiplex approach for use in its services. The approach leverages traditionally validated antibodies along with standard fluorescent imaging equipment such that it can be easily applied to any therapeutic area of interest. To accomplish multiple rounds of labeling, the technique relies upon the use of a proprietary antibody stripping reagent which removes the primary and secondary antibodies without damaging the tissue or epitopes. After multiple rounds of labeling and imaging are conducted, the data sets are aligned using an elastic co-registration approach that Visikol has developed such that the whole data set can be used to address a researcher’s question. For example, assessing the variety and distribution of immune cells within and around tumor tissue.

This multiplex approach is an addition to Visikol’s advanced imaging services suite and pairs with its pipeline of 2D and 3D digital pathology software that allows the Visikol team to transform terabytes of data into actionable insights for a Client. The company also provides its Clients with access to Imaging Mass Cytometry services if they want to achieve 30+ plex multiplex slide imaging in tandem or in lieu of the Visikol approach and other endpoints.

“As a leading imaging and digital pathology CRO, we always want to provide our Clients with a diverse set of tools such that they can choose the specific tool that best meets their research needs as well as their cost and throughput requirements. For example, one researcher might require whole slide imaging but only six labels at a time and would use the Visikol approach where another researcher might have a block of tissue micro arrays and want to image each for 35 labels and use imaging mass cytometry instead,” described Visikol CEO Michael Johnson, PhD.

There are three steps to starting a multiplexing project with Visikol. First, the researcher discusses with Visikol their specific project needs and the Visikol team conducts a small initial validation study with control samples to demonstrate the labeling panels are effective. After the panels have been validated, they are applied to the researcher’s tissues of interest to generate imaging data and lastly the imaging data is analyzed using Visikol’s 3Screen™ image analysis software to create a quantitative report addressing the researcher’s key questions.

About Visikol

Visikol is a contract research organization (CRO) focused on advanced drug discovery that is leading the fields of bioimaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative datasets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

Share article on social media or email:

ASHA, Allied Provider Groups Urge Legislative Action to Protect Medicare Beneficiaries’ Access to Services


The clock is ticking—these cuts will be implemented in 30 days. AOTA, APTA, and ASHA urge Congress to include H.R. 8702, the Holding Providers Harmless from Medicare Cuts During COVID-19 Act of 2020, in any moving legislative vehicle before the end of the year.

In a move that will restrict Medicare beneficiaries’ access to a host of medically necessary services, the Centers for Medicare & Medicaid Services (CMS) yesterday formalized significant payment reductions to more than three dozen health care provider groups for 2021. Audiologists will suffer a 6% cut and speech-language pathologists a 9% cut to Medicare reimbursement for their services. These reductions stand to put patients in jeopardy and risk the economic viability of health care practices, according to the American Speech-Language-Hearing Association (ASHA).

ASHA, the American Occupational Therapy Association (AOTA), and the American Physical Therapy Association (APTA) are calling on Congress to take immediate action to offset the cuts in CMS’s 2021 Medicare Physician Fee Schedule. In a joint statement issued last night, the associations note: “The clock is ticking—these cuts will be implemented in 30 days. AOTA, APTA, and ASHA urge Congress to include H.R. 8702, the Holding Providers Harmless from Medicare Cuts During COVID-19 Act of 2020, in any moving legislative vehicle before the end of the year. H.R. 8702 is bipartisan legislation that will address these cuts by providing relief payments in an amount that will ensure parity with current payment for impacted services.”

The groups explain: “Our members serve a critical role in the health and vitality of this nation, frequently evaluating and treating older adults with physical, cognitive, communication, psychosocial, hearing, and balance disorders. Our services help ensure that these beneficiaries have the functional stability required to remain safe and independent within their communities. The care we provide is all the more important to patients recovering from COVID-19.”

ASHA also joined a larger coalition of physician and nonphysician provider groups who are decrying CMS’s final rule. In a separate statement, these groups assert: “Thousands of comments submitted by providers, patients, and Members of Congress highlighted the importance of mitigating payment cuts associated with budget neutrality requirements triggered by higher payment and modified reporting requirements for evaluation and management (E/M) services. Due to CMS’s unresponsiveness to address these concerns, organizations representing more than 1 million physicians and nonphysician health care providers across the United States urge Congress to include legislation in any year-end package to prevent these arbitrary Medicare cuts in order to protect patient access to medically necessary services.”

According to ASHA, the timing of the cuts is especially bad, given that the pandemic is disproportionately impacting older Americans and that many health care practices have already reduced their staffs or shuttered due to economic strains of COVID-19. Cuts to reimbursement will compound this situation, making it even more difficult for patients to receive needed care. Those in rural and underserved areas would be the hardest hit.

For more information, visit ASHA’s website.

About the American Speech-Language-Hearing Association (ASHA)

ASHA is the national professional, scientific, and credentialing association for 211,000 members and affiliates who are audiologists; speech-language pathologists; speech, language, and hearing scientists; audiology and speech-language pathology support personnel; and students. Audiologists specialize in preventing and assessing hearing and balance disorders as well as providing audiologic treatment, including hearing aids. Speech-language pathologists identify, assess, and treat speech and language problems, including swallowing disorders. http://www.asha.org

###

Share article on social media or email:

RARE-X, Launches First Research Pilot Projects For Rare Disease


News Image

“This data collection initiative significantly changes the outlook for patient communities needing treatments, and for researchers and drug developers working to find and develop those therapies.” – Nicole Boice, RARE-X Co-Founder/Executive Director.

RARE-X, a collaborative platform for patient-controlled and structured data collection, global data sharing and analysis that will accelerate treatments for rare diseases, announces the launch of its 2021 priorities and pilots made possible by critical early-stage funding from Alexion – a leading global biopharmaceutical company focused on the development of medicines for rare diseases and devastating conditions.

The RARE-X technology platform is specifically designed to:

  • Spur the development and sharing of data sets that aren’t currently being generated, connected, properly structured and curated, or made accessible to enable meaningful research;
  • Level the playing field for patient communities that might not otherwise have the opportunity to participate effectively in pivotal research on their behalf;
  • Expand the usability, visibility, and reach of data from existing research programs, registries, and other aggregation efforts, thereby eliminating silos that may keep a brilliant researcher from a game-changing discovery or an innovative company from seeing the possibilities in a disease area needing a therapy;    
  • Support patients in responsible data ownership and sharing

“This data collection initiative significantly changes the outlook for patient communities needing treatments, and for researchers and drug developers working to find and develop those therapies,” said Nicole Boice, RARE-X Co-Founder/Executive Director. “RARE-X positions patients everywhere to become central drivers in the efforts to progress research in their disease. RARE-X will also be supporting cross-disease research for rare conditions, as well as creating greater efficiencies that will result in a more effective and collaborative research ecosystem. A core RARE-X guiding principle is that patients own their own data, and in doing so, hold a central position in enabling research and drug discovery, to advance care and the next generation of therapies for the disease they care about.”

The RARE-X platform for data contribution, aggregation, analytics, and research is powered by Broad Institute technology and expertise, which has successfully been implemented in other large-scale public data-sharing efforts. Designed to support data collection at scale, the RARE-X Data Collection Platform will have the capability to interconnect, structure, and securely accommodate a wide range of data, from genomic and clinical to patient-reported outcomes and even wearable or digital exhaust data. The types of data contributed and accessed via RARE-X will be entirely at the discretion of participating patients/patient communities and other data owners. The goal is to help enable a vibrant ecosystem of discovery needed to support the development of future cures. The core governance principles are patient-centered and intended to meet the most stringent global standards, and have been similarly tested via other major public sector data initiatives.

“For more than 25 years, Alexion has been focused on serving patients with rare diseases and devastating conditions by developing transformative medicines, and in this time, we have made significant advances and delivered life-changing medicines to thousands of patients globally,” said Wendy Erler, Vice President, Patient Experience at Alexion. “However, we recognize there is a lot more work to be done to help those living with undiagnosed rare diseases and those who still do not have a therapy today. We are proud to support the work of RARE-X, the rare disease communities, and the goal of accelerating the development of new medicines for rare diseases by empowering patients to share their data.”

As RARE-X initiates its 24-month pilot period, to demonstrate how this new approach to patient-owned data collection and federated data sharing for biomedical research will accelerate disease understanding and therapy development, RARE-X will showcase the platform scalability that will efficiently support thousands of global data collection portals and patients. Key priorities include:

  • Structured Data by domain – launching in Neurology, followed by four additional domain areas through the end of 2021
  • Twenty (20) neurology-focused data collection portals – disease areas to be announced in early 2021
  • Five (5) collaborative demonstration projects will leverage the entire technology platform supporting 21st-century data collection and federated data sharing globally—partners to be announced in early 2021.
  • Scoping the first international patient owned data collection effort, with the release of a landscape report in collaboration with RARE-X founding partner, IndoUSrare.

Early RARE-X collaborators have embraced this innovative approach to transform the rare disease research landscape, including an extraordinary Board of Directors and Advisors. Other organizational collaborators include: The Alliance for AI in Healthcare, The ARM Foundation for Cell and Gene Medicine, The Broad Institute Data Sciences Division, Global Genes, Sanford Health, and additional partners being announced over the next several months.

For partnership inquiries and to support this growing effort please contact the RARE-X team at collaborators@rare-x.org.

ABOUT RARE-XTM

RARE-X is a 501(c)(3) patient advocacy organization focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by rare disease. Enabled by best-in-class technology, patients, researchers, and other technology vendors, RARE-X will gather structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. RARE-X is building the largest collaborative patient-driven, open-data access project for rare diseases globally. For more information, visit tomh@rare-x.org http://www.rare-x.org.

Media Contact:

Tom Hume, Marketing Communications – RARE-X

tomh@rare-x.org

Share article on social media or email:

ConnectWell and Outgrow Introduce Turnkey Interactive Digital Health Tools to Re-engage People Delaying Health Care Due to Pandemic


News Image

The suite of turnkey interactive digital health tools developed by ConnectWell and Outgrow include virtual risk assessments for 11 conditions that impact a large portion of the U.S. population.

The value of these tools stems from Outgrow’s track record of creating engaging interactive experiences that prompt user action combined with ConnectWell’s expertise in developing consumer-friendly digital health content, which is expertly sourced from the UC Berkeley School of Public Health.

Amidst a pandemic in which many Americans are delaying medical care due to COVID-19 concerns, ConnectWell, a leading-edge provider of digital health and wellness content, and Outgrow, a leader in creating interactive online experiences, today introduced a suite of turnkey interactive digital health tools designed to re-engage, educate, and connect people to care. The companies co-developed the new virtual tools for healthcare providers, health plans, employers, and benefits providers seeking to re-engage those they serve using evidence-based health and wellness information as the driver and the means to access care.

The U.S. Centers for Disease Control and Prevention (CDC) reported that by the end of Q2 this year, 41 percent of U.S. adults acknowledged that they had delayed or avoided healthcare due to concerns related to COVID-19.* Separately, a study of primary care revealed that during the same quarter, even with exponential growth in telehealth appointments, there was still a 21.4 percent decline in primary care visits overall in the U.S. compared to Q2 in 2018 and 2019. Vital health measurements connected with those Q2 visits also declined, with decreases of 50.1 and 36.9 percent in blood pressure and cholesterol checks, respectively.**

While the kind of user-friendly interactive tools provided by the ConnectWell-Outgrow suite are useful for reconnecting anyone to care, they are especially vital for re-engaging people with COVID-related health risks to help them bolster their health and better protect themselves during a surging pandemic.

“The value of these tools stems from Outgrow’s track record of creating engaging interactive experiences that prompt user action combined with ConnectWell’s expertise in developing consumer-friendly digital health content, which is expertly sourced from the UC Berkeley School of Public Health, a pioneer in creating evidence-based health and wellness information,” said Andrea Bloom, Founder and CEO of ConnectWell.

The interactive digital health tools have three components—risk assessments, knowledge tests, and reading recommendations that inform and educate people on 11 key conditions. These conditions represent COVID-19 health risks that impact a significant portion of the U.S. population, including diabetes, hypertension, obesity, high cholesterol, coronary heart disease, heart attack, stroke, lung infection, asthma, COPD, and depression. Healthcare organizations, benefits providers, and employers can use these interactive digital health tools with their populations virtually. This enables patients, employees, and health plan members to safely assess their risk online for these manageable conditions. The tools will also provide them with the opportunity to learn more about conditions that warrant attention, and reduce their risk of delaying diagnosis or serious complications by seeking follow-up care.

“Working jointly with ConnectWell, our aim has been to enable Health and Wellness companies and HR departments to educate their patients and employees to learn about health risks and best practices for a healthy lifestyle,” said Randy Rayess, Co-founder of Outgrow. “We do this by providing access to vetted health content from the UC Berkeley School of Public Health, including knowledge surveys, risk assessments, and article recommendations, while helping people take the next steps in connecting with the care they need.”

Healthcare organizations understand the need for these kinds of virtual care tools, yet to create them from the ground up would require extensive resources during a time when healthcare organizations are already stretched thin. It requires contracting with both an interactive software platform and a digital health content provider, then securing or allocating significant internal resources with expertise in content and software development as well as health condition management.

The ConnectWell-Outgrow suite of digital health tools, on the other hand, is a turnkey solution that comes fully developed from collaborators with top-tier expertise in creating interactive digital engagement experiences and expertly sourced and vetted consumer health content. And the tools are customizable, enabling companies to steer those they serve to connect with the care they need, based on their risk assessments. This can include prompts for scheduling lab tests and appointments with appropriate providers, connecting users with a call center, arranging for health coaching, and more. The ConnectWell-Outgrow suite also provides reporting and analytics, enabling customers to gain insights on the usage of the tools as well as the population health data of users on an aggregate level.

The ConnectWell-Outgrow digital health tools can be integrated with the virtual care experience of a range of organizations. Healthcare providers are looking to reconnect, re-engage, and restore interactions with patients who have dropped off. Health plans are seeking to keep member populations healthy through a digital delivery option. Employers are working to keep office-based and remote employees healthy, productive, and safe. Whereas benefit providers are looking to bundle interactive digital health tools with their wellness program and benefits packages.

ConnectWell and Outgrow are building out these turnkey digital health tools across dozens of health conditions to expand this initial launch and further engage people in care through early detection and intervention. To learn more about the ConnectWell-Outgrow interactive digital health tools, please visit the page about the tools on the ConnectWell website.

About ConnectWell

ConnectWell is a leading-edge provider of digital health and wellness content that is academically sourced and designed for a consumer audience to engage people in their total health and well-being. ConnectWell’s public-private partnership with the UC Berkeley School of Public Health guarantees access to a vast library of health and wellness content that is continually reviewed and updated to include the latest standard of care guidelines and scientific findings on health, wellness, and disease management. ConnectWell licenses its content to healthcare providers, health plans, telemedicine providers, wellness engagement platforms, health device companies, employers, and benefits providers to engage their target audiences in their health and well-being.

About UC Berkeley School of Public Health and Health & Wellness Publications

For more than 70 years, the UC Berkeley School of Public Health has been a leading institution in public health education and research, contributing to the improved health and welfare of communities, the state, and the world. The Health & Wellness Publications of the School of Public Health date back to 1984, when the Berkeley Wellness Letter was founded. UC Berkeley experts carefully examine the latest health and wellness information so readers can make quality lifestyle choices and self-care decisions.

About Outgrow

Outgrow has been the G2 Crowd Market Leader in the interactive industry for 3 years in a row and has been ranked the #1 B2B Tech Company in New York. Outgrow’s interactive experiences have a proven record of increasing engagement, providing personalized value to every single person, increasing the time they spend on your educational efforts, the value they receive and their chances of making positive changes in their lives.

Media Contact:

Jeff Christensen

SignalWest Public Relations

Email: Jeff@SignalWestPR.com

Mobile: 831.566.0275

*“Delay or Avoidance of Medical Care Because of COVID-19–Related Concerns — United States, June 2020,” Morbidity and Mortality Weekly Report, U.S. Centers for Disease Control and Prevention, 11 Sept. 2020

**“Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US,” JAMA Network Open, 2 Oct. 2020

Dental Implants of Ocala Improves Overall Health with Permanent Dental Implants in Ocala, FL


Dr. Nickelice Brand, Dental Implant Dentist in Ocala, FL

Dr. Nickelice Brand Improves Oral Health with Dental Implants in Ocala, FL

Overall, in addition to providing permanent restoration of function and aesthetics, dental implants can help improve oral health, systemic health, and the immune system.

Drs. Nickelice Brand and Eric Rustemier, esteemed implant dentists at Dental Implants of Ocala, raise awareness of how oral disease and tooth loss negatively affect oral health and the immune system. They provide dental implants in Ocala, FL to permanently replace missing teeth and improve overall health during the COVID-19 pandemic.

Tooth loss can occur for many reasons, but the most common reasons include gum disease, decay due to neglected oral health, or a tooth abscess that requires extraction. In cases involving infection and disease, whole-body health can also be negatively affected. Bacteria from gum disease, the most common cause of tooth loss, can spread throughout the mouth and body via the bloodstream. Left untreated, gum disease can damage oral structures, lead to loose teeth and tooth loss, and diminish systemic health, including the body’s immune system. In most cases, Drs. Brand and Rustemier recommend dental implants to permanently restore oral health and improve overall health and immunity, especially during the COVID-19 pandemic.

Dental implants are permanent tooth replacements that are surgically placed into the jawbone. They can replace one, several, or an entire mouth of missing teeth with a comparable level of durability, aesthetics, and strength. Unlike partials and dentures, dental implants are permanently fixed in the jaw like natural teeth and allow for proper biting and chewing of nutritious, healthy food. When implants replace infected or decayed teeth, dangerous bacteria from the mouth is removed, improving oral health and overall health. For individuals who have multiple failing or missing teeth as a result of gum disease or decay, full mouth dental implants provide a permanent improvement in dental function, natural smile aesthetics, and oral health. Overall, in addition to providing permanent restoration of function and aesthetics, dental implants can help improve oral health, systemic health, and the immune system.

Dental Implants of Ocala offers decades of experience in implant dentistry and solely provides comprehensive dental implant treatment. Drs. Brand and Rustemier place thousands of dental implants each year, with a specialization in full mouth dental implants, and maintain an over 98 percent success rate. Using innovative technologies, including custom surgical guides and bone morphogenetic protein, the implant dentists provide customized and predictable treatment that permanently restores each of their patient’s smiles, health, and quality of life. In light of the COVID-19 pandemic, the team continues to practice advanced safety and sanitization measures for the health and safety of their staff and patients.

Individuals with tooth loss who are interested in improving their health, immunity, and quality of life can schedule a consultation for dental implants in Ocala, FL by visiting http://www.dentalimplantsofocala.com or calling 352-653-2500.

About the Practice

Dental Implants of Ocala offers all-inclusive dental implant treatment to patients of Marion County, including Ocala, FL, The Villages, and beyond. Dr. Nickelice Brand, the practice’s leading implant dentist, has over 25 years of experience and focuses solely on providing innovative implant solutions for his patients. Placing over 1000 dental implants a year, Dr. Brand has retained a 98 percent implant success rate and an even higher level of patient satisfaction. Dr. Eric Rustemier graduated from the University of Louisville and received the prestigious Dawson Scholar Award, which is awarded to two dental students in the country per year in recognition of commitment and achievement in clinical comprehensive dentistry and temporomandibular disorders. Dr. Rustemier is an avid pursuer of knowledge and completes over 100 hours of continuing dental education each year. The team at Dental Implants of Ocala remains up to date on implant dentistry’s most innovative and unique technologies, including bone morphogenetic protein and CeraRoot ceramic dental implants, to ensure the highest standard of care and most predictable treatment outcomes. To learn more about Dental Implants of Ocala and their innovative implant care, visit http://www.dentalimplantsofocala.com or call 352-653-2500.                                                                     

Share article on social media or email:

The Periodontists at Shoreline Periodontics and Dental Implants in New London, CT Host Virtual Study Club on Cultural Competency


Drs. Marianne Urbanski and Gregory Toback, Periodontists in New London, CT

Periodontists, Drs. Marianne Urbanski and Gregory Toback, Host Virtual Study Club on Cultural Competency

Instead of scalpels and sutures, this innovative technology uses laser energy to gently and effectively clear away the bacteria responsible for gum disease.

Periodontists Dr. Gregory A. Toback and Dr. Marianne Urbanski of Shoreline Periodontics and Dental Implants in New London, CT and Westerly, RI, went virtual when they hosted a recent 2020 Hygiene Study Club seminar. Offered exclusively to local dentists and dental hygienists in Southeastern CT and RI, this session fulfilled cultural competency continuing education (CE) requirements.

“Cultural Competency” featured guest speaker Cathie Collier, RDH BEd, a well-known dental hygiene educator. The seminar covered verbal and nonverbal communication with patients from diverse cultures and how this is integral to understanding the reason behind their healthcare decisions and values. Participants learned strategies for effective communication by using different styles and skills to overcome potential cultural barriers. Drs. Toback and Urbanski believe that good communication is as integral to delivering compassionate care as leveraging state-of-the-art gum disease treatments.

Shoreline Periodontics offers permanent dental implants and periodontal disease (gum disease) treatment, including advanced LANAP® laser dentistry. LANAP is a minimally invasive alternative to osseous surgery. Instead of scalpels and sutures, this innovative technology uses laser energy to gently and effectively clear away the bacteria responsible for gum disease. This approach results in less pain, postop sensitivity, and gum loss, as well as greatly decreased downtime after treatment.

In addition to good communication, safety is also a top priority, which is why the Shoreline Periodontics Hygiene Study Club was presented virtually. The practice has also taken extra steps to protect patients during the coronavirus pandemic. In addition to following infection control recommendations from the ADA, CDC, and OSHA, the number of people allowed in the office is limited.

To learn more about Shoreline Periodontics, their compassionate periodontists, and cutting-edge services, visit their website at http://www.shorelineperio.com or call 860-443-2428 for the New London, CT location, or 401-596-0000 for the Westerly, RI office.

About the Periodontists

Shoreline Periodontics is a periodontal practice offering personalized dental care for patients since 1998 and is located in New London, CT and Westerly, RI. Leading board-certified periodontist, Dr. Gregory A. Toback, received his B.A. from St. John’s University and his Doctorate of Dental Medicine from the University of Connecticut. He also received advanced training in periodontics and dental implants at the University of Texas Health Science Center in San Antonio. Dr. Marianne Urbanski has been voted one of Connecticut’s top dentists for more than seven years by Connecticut Magazine. Dr. Urbanski graduated cum laude from the College of Holy Cross in Worcester, Massachusetts where she earned a Bachelors’ degree in Biology. She also received her Doctor of Dental Medicine degree and her Masters’ of Dental Science degree from the University of Connecticut Dental School. Dr. Urbanski and Dr. Toback pride themselves on offering caring, professional treatment to each patient. Dr. Toback and Dr. Urbanski focus on minimally invasive surgeries including LANAP® laser gum surgery and are certified to offer the Chao Pinhole Surgical Technique™ for treatment of gum recession. To learn more about Shoreline Periodontics and their dental services visit their website at http://www.shorelineperio.com or call 860-443-2428 for the New London, CT location, or 401-596-0000 for the Westerly, RI office.

Share article on social media or email: